Effects of Retrovirus Protein on the Feline One-way Mixed Leukocyte Reaction

By MARY I. STIFF* AND RICHARD G. OLSEN1,2

1 Department of Veterinary Pathobiology, The Ohio State University, 1925 Coffey Road, Columbus, Ohio 43210 and 2 Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, U.S.A.

(Accepted 3 December 1982)

SUMMARY

The objective of this study was to evaluate the effects of feline retrovirus protein on cat lymphocyte recognition of allogeneic cells in the mixed leukocyte reaction (MLR), using u.v.-inactivated feline leukaemia virus (FeLV) and a non-disease-producing endogenous cat virus (RD-114). Twenty micrograms of u.v.-inactivated virus protein from each virus were added to mixed leukocyte cultures. FeLV induced significant suppression of the MLR (P < 0.005) whereas no significant suppression was found using RD-114. Since feline leukaemia infection is associated with immunosuppression, the retrovirus proteins may be interfering with the response of immunocompetent cells when they are confronted with an altered host cell.

The purpose of this research was to study the effects of u.v.-inactivated retroviruses (FeLV and RD-114) on the feline mixed leukocyte reaction (MLR); an in vitro correlate of cell-mediated immunity (McDevitt, 1978) and immunosurveillance (Burnet, 1970).

Feline leukaemia virus-infected cats have been shown to demonstrate suppressed allograft rejection (Perryman et al., 1972). Subsequently, Cockerell et al. (1976) found that the in vitro lymphocyte blastogenic responses to T-cell mitogens were suppressed in viraemic cats even though the T-cell population remained relatively constant. To determine whether this suppression in cats was due to virus protein, Hebebrand et al. (1977) used u.v.-inactivated FeLV in in vitro mitogenic studies and noted suppression of normal mitogenic responses with 20 μg/well of virus protein. Characterization of a particular immunosuppressive envelope protein (p15E) has been accomplished by Hebebrand et al. (1979) and Mathes et al. (1978, 1979).

This research has investigated the possibility that feline leukaemia virus proteins may interfere with cellular immunity in cats as evaluated by the MLR.

The feline one-way MLR was performed as a modification of the human MLR (O'Leary et al., 1977). Briefly, defibrinated venous blood was obtained from specific-pathogen-free cats (SPF; over 6 months old) (Rohovsky et al., 1966) using aseptic technique. Diluted blood was layered over Ficollpaque (Pharmacia) and centrifuged (Cockerell et al., 1975). The leukocyte-rich interface was recovered, cells were washed and diluted in RPMI 1640 medium with 25 mM-HEPES buffer (Grand Island Biological Co.). Stimulators were treated with mitomycin C (Sigma) at 0.05 mg/10⁷ cells. One-tenth ml of each cell suspension (10⁵ cells) was placed in plastic round-bottom microtitre plates (Linbro Division, Flow Laboratories) and incubated for 9 days at 37 °C in 2.5% CO₂, moist air. During the last 18 h of incubation, 0.5 μCi [³H]thymidine (6.7 Ci/mol; New England Nuclear) was added. Cells were collected and assayed for radioactivity by liquid scintillation. Each sample was counted for 5 min and net ct/min of quadruplicate wells were recorded. All autologous controls were tested along with the allogeneic combinations. Five percent rabbit serum (heat-inactivated) was added as the serum supplement. Viruses used in vitro were the feline leukaemia virus (KT strain, supplied by Pfizer, Inc., Maywood, N.J., U.S.A. through the auspices of the virus cancer program of the National Cancer Institute) and RD-114 (from RD-RD114 cell line supplied by Pfizer). RD-114 virus was
purified by banding twice in sucrose. FeLV was banded in sucrose once, since twice banding causes no significant differences in tissue culture studies. Whole viruses were u.v.-inactivated and dialysed (Mathes et al., 1978).

MLR's were done on a number of cats to locate allogeneic combinations that result in stimulation. Initially, dose titration experiments were done using 0, 5, 10 or 20 µg virus protein/well with these allogeneic combinations. The RD-114 virus proteins caused no significant suppression of the MLR at any of the concentrations, although slight suppression was noted at 20 µg/well. In comparison, the FeLV proteins caused significant suppression at 5 µg/well (P < 0.05, Student's t-test), 10 µg/well (P < 0.005) and 20 µg/well (P < 0.001) (Fig. 1). Viability experiments (trypan blue exclusion) indicated that this suppression was not due to virus-induced cytotoxicity.

Additional studies were done using media (control) or 20 µg/well of each virus protein preparation in the same allogeneic combinations simultaneously. A significant suppression of the MLR with u.v.-inactivated FeLV (P < 0.005) occurred compared to the test without virus, whereas RD-114 did not significantly suppress the response (P < 0.1) (Fig. 2).

In these experiments RD-114, an endogenous cat virus, did cause some suppression in the MLR. It is not known whether this decrease in MLR was caused by an immunosuppressive protein which is less effective than that found with FeLV or simply the presence of extraneous protein in the reaction system. However, it is clear that FeLV virus proteins cause greater immunosuppression of the cat MLR than the endogenous cat retrovirus (RD-114) which has not been shown to cause any disease (Gardner et al., 1974).

In studies of the murine leukaemia viruses, Cianciolo et al. (1980) found that the subviral proteins (including p15E) inhibited macrophage function in the inflammatory response. Therefore, it is possible that the feline leukaemia subvirus proteins are interfering with the monocyte's role in the MLR (Bach, 1976).

In addition to suppression of lymphocyte blastogenic transformation (Hebebrand et al., 1979; Olsen et al., 1980), allograft rejection (Perryman et al., 1972), and lymphocyte capping (Dunlap et al., 1979), we find that FeLV virus proteins also suppress the cell-mediated response of the MLR. These data therefore suggest that FeLV virus protein may inhibit the lymphocyte response to transformed or virus-infected cells.
This work was supported in part by Public Health Service grants CA-31547, CA-30338, grant NO1-CP91008 of the National Cancer Institute, National Institutes of Health, and a grant from the Norden Corporation, Lincoln, Nebraska, U.S.A.

REFERENCES


(Received 18 June 1982)